Table 1.

Ganglionic AChR antibody in patients with dysautonomia and other disorders^*

Diagnostic Group	% seropositive	Antibody levels	Reference
Autonomic disorders
Subacute AAG	40 – 50%	0.5 – 41.0 nM/L	(Vernino et al., 2008; Vernino et al., 2000)
Chronic AAG	30 – 40%**	0.2 – 5.0 nmol/L	(Klein et al., 2003)
Paraneoplastic AAG	10 – 20%	0.2 – 20.0 nmol/L	(Vernino et al., 2000)
Postural tachycardia syndrome (POTS)	10 – 15%	< 0.25 nmol/L	(Thieben et al., 2007)
Idiopathic gastrointestinal dysmotility	5 – 10%	< 0.4 nmol/L	(Vernino et al., 2000)
Diabetic autonomic neuropathy	< 10%
Multiple system atrophy (Shy-Drager)	0
Other disorders
Lambert-Eaton syndrome	5 – 10%	0.06 – 0.4 nmol/L	(Vernino et al., 2000)
Myasthenia gravis without thymoma	3%	< 0.25 nmol/L	(Vernino et al., 2008)
Paraneoplastic disorders with thymoma	15 – 20%	0.06 – 2.0 nmol/L	(Vernino et al., 2004b)
Paraneoplastic disorders with SCLC	3 – 5%

^*None of over 200 healthy control subjects were seropositive for ganglionic AChR antibodies.

^**The exact frequency is not known since antibody status may affect case definition